Tenon Medical Reports Record Q1 2026 Earnings with Strong Growth Drivers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy TNON?
Source: seekingalpha
- Significant Revenue Growth: Tenon Medical reported first-quarter revenue of $1.4 million for 2026, marking the highest first-quarter revenue in the company's history, driven by an increase in Catamaran cases and meaningful contributions from SImmetry+, which are expected to support continued growth.
- Margin Expansion: The company achieved a gross margin of 68.5%, attributed to spreading fixed production costs over a larger revenue base, with expectations for further margin expansion as revenue scales, enhancing overall profitability.
- Financing for Expansion: In March, the company closed a $4.3 million senior convertible note placement, providing the necessary capital to support commercial expansion, product launches, and clinical programs without further distractions, ensuring operational flexibility.
- Positive Future Outlook: While management did not issue formal revenue or EPS guidance, they highlighted the full commercial launch of SImmetry+ and the Alpha phase of new technology, which are anticipated to drive sustained growth into the second half of 2026 and beyond.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNON
Wall Street analysts forecast TNON stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.814
Low
2.50
Averages
2.75
High
3.00
Current: 0.814
Low
2.50
Averages
2.75
High
3.00
About TNON
Tenon Medical, Inc. is a medical device company. The Company has developed the Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Its trademarks include Catamaran, PiSIF, CAT PiSIF, ETAD, CAT SIJ Fusion System, SImmetry, MAINSAIL, SImmetry+, Catamaran Transfixation Fusion Device, Catamaran Transfixation Fusion System, and others. The Catamaran SI Joint Fusion System offers a novel, less invasive Inferior-Posterior approach to the SI joint using a single, robust titanium implant.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tenon Medical Reports Q1 Earnings Beat with Significant Revenue Growth
- Earnings Performance: Tenon Medical reported a Q1 GAAP EPS of -$0.31, missing expectations by $0.01, indicating ongoing challenges in profitability despite revenue growth.
- Revenue Surge: The company achieved $1.4M in revenue for the first quarter, representing a 91.8% year-over-year increase and exceeding market expectations by $0.1M, highlighting significant progress in market demand.
- Margin Improvement: Gross profit for Q1 was $0.9M, or 68.5% of revenue, up from $0.3M and 44.5% a year earlier, reflecting a 24 percentage point improvement driven by enhanced production efficiency and cost absorption.
- Strategic Growth: Following a 92% revenue increase in Q4 2025 and the expansion of its SI-Joint Fusion portfolio, Tenon Medical demonstrates a proactive strategic approach to accelerate growth and market expansion.
See More
Tenon Medical Reports Record Q1 2026 Earnings with Strong Growth Drivers
- Significant Revenue Growth: Tenon Medical reported first-quarter revenue of $1.4 million for 2026, marking the highest first-quarter revenue in the company's history, driven by an increase in Catamaran cases and meaningful contributions from SImmetry+, which are expected to support continued growth.
- Margin Expansion: The company achieved a gross margin of 68.5%, attributed to spreading fixed production costs over a larger revenue base, with expectations for further margin expansion as revenue scales, enhancing overall profitability.
- Financing for Expansion: In March, the company closed a $4.3 million senior convertible note placement, providing the necessary capital to support commercial expansion, product launches, and clinical programs without further distractions, ensuring operational flexibility.
- Positive Future Outlook: While management did not issue formal revenue or EPS guidance, they highlighted the full commercial launch of SImmetry+ and the Alpha phase of new technology, which are anticipated to drive sustained growth into the second half of 2026 and beyond.
See More
Tenon Medical to Release Q1 2026 Financial Results on May 12
- Financial Release Schedule: Tenon Medical plans to release its financial results for Q1 2026 after market close on May 12, 2026, which will provide critical financial data to assess the company's performance.
- Conference Call Details: A conference call will be held on the same day at 4:30 PM Eastern Time, where management will discuss the financial results in detail and engage in a Q&A session with analysts, enhancing investor understanding of the company's operations.
- Technological Innovation Background: Tenon Medical focuses on developing innovative medical devices for sacroiliac joint disorders, launching the Catamaran® and SImmetry+® systems that offer less invasive treatment options aimed at improving patient outcomes and satisfaction.
- Market Opportunity Analysis: The company targets three commercial opportunities in the sacroiliac joint market: primary procedures, revision of failed implants, and augmenting spinal fusion, demonstrating its strategic positioning in the rapidly growing medical device market.
See More
Tenon Medical Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: Tenon Medical achieved a full-year revenue of $3.9 million in 2025, marking a 20% increase compared to 2024, with fourth-quarter revenue reaching $1.5 million, a remarkable 92% growth driven by increased surgical procedures and new physician users.
- Improved Gross Margin: The company reported a gross profit of $1 million in Q4 2025, representing 69% of revenue, a substantial increase from 46% in Q4 2024, indicating progress in cost control and sales efficiency.
- Enhanced Financial Flexibility: Tenon Medical successfully completed a $2.85 million At-The-Market PIPE financing and a $4.3 million private placement of senior convertible notes, providing the financial flexibility necessary for expansion and product rollouts, laying a solid foundation for future growth.
- Net Loss Improvement: Although the company reported a net loss of $12.6 million for the full year 2025, this reflects an improvement from a $13.7 million loss in 2024, demonstrating the company's efforts and effectiveness in controlling losses.
See More
Tenon Medical (TNON) Q4 2025 Earnings Transcript
See More
Tenon Medical Reports Record Q4 2025 Revenue Growth and Strategic Developments
- Record Revenue Growth: Tenon Medical achieved a full-year revenue of $3.9 million in 2025, marking a 20% increase, with Q4 revenue reaching $1.5 million, a 92% rise year-over-year, indicating significant growth driven by increased surgical procedures across the Catamaran and SImmetry+ platforms.
- FDA 510(k) Clearance Milestone: The company received FDA 510(k) clearance for the next-generation SImmetry+ SI-Joint Fusion System, expanding its portfolio to include a complementary lateral approach alongside Catamaran, which is expected to drive future market demand and revenue growth.
- Financing and Investment Plans: Tenon completed a $2.85 million At-The-Market PIPE financing and a $4.3 million private placement of senior convertible notes, with proceeds aimed at funding commercial expansion, product launches, and clinical studies, ensuring the company’s ongoing growth and innovation capabilities.
- Gross Margin Improvement: The gross profit for Q4 was $1 million, representing 69% of revenue, a significant increase from 46% in the prior year, reflecting the company's success in cost control and operational efficiency, which is expected to lay the foundation for sustainable growth in 2026.
See More
Tenon Medical Reports Q1 Earnings Beat with Significant Revenue Growth
- Earnings Performance: Tenon Medical reported a Q1 GAAP EPS of -$0.31, missing expectations by $0.01, indicating ongoing challenges in profitability despite revenue growth.
- Revenue Surge: The company achieved $1.4M in revenue for the first quarter, representing a 91.8% year-over-year increase and exceeding market expectations by $0.1M, highlighting significant progress in market demand.
- Margin Improvement: Gross profit for Q1 was $0.9M, or 68.5% of revenue, up from $0.3M and 44.5% a year earlier, reflecting a 24 percentage point improvement driven by enhanced production efficiency and cost absorption.
- Strategic Growth: Following a 92% revenue increase in Q4 2025 and the expansion of its SI-Joint Fusion portfolio, Tenon Medical demonstrates a proactive strategic approach to accelerate growth and market expansion.
See More
Tenon Medical Reports Record Q1 2026 Earnings with Strong Growth Drivers
- Significant Revenue Growth: Tenon Medical reported first-quarter revenue of $1.4 million for 2026, marking the highest first-quarter revenue in the company's history, driven by an increase in Catamaran cases and meaningful contributions from SImmetry+, which are expected to support continued growth.
- Margin Expansion: The company achieved a gross margin of 68.5%, attributed to spreading fixed production costs over a larger revenue base, with expectations for further margin expansion as revenue scales, enhancing overall profitability.
- Financing for Expansion: In March, the company closed a $4.3 million senior convertible note placement, providing the necessary capital to support commercial expansion, product launches, and clinical programs without further distractions, ensuring operational flexibility.
- Positive Future Outlook: While management did not issue formal revenue or EPS guidance, they highlighted the full commercial launch of SImmetry+ and the Alpha phase of new technology, which are anticipated to drive sustained growth into the second half of 2026 and beyond.
See More
Tenon Medical to Release Q1 2026 Financial Results on May 12
- Financial Release Schedule: Tenon Medical plans to release its financial results for Q1 2026 after market close on May 12, 2026, which will provide critical financial data to assess the company's performance.
- Conference Call Details: A conference call will be held on the same day at 4:30 PM Eastern Time, where management will discuss the financial results in detail and engage in a Q&A session with analysts, enhancing investor understanding of the company's operations.
- Technological Innovation Background: Tenon Medical focuses on developing innovative medical devices for sacroiliac joint disorders, launching the Catamaran® and SImmetry+® systems that offer less invasive treatment options aimed at improving patient outcomes and satisfaction.
- Market Opportunity Analysis: The company targets three commercial opportunities in the sacroiliac joint market: primary procedures, revision of failed implants, and augmenting spinal fusion, demonstrating its strategic positioning in the rapidly growing medical device market.
See More
Tenon Medical Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: Tenon Medical achieved a full-year revenue of $3.9 million in 2025, marking a 20% increase compared to 2024, with fourth-quarter revenue reaching $1.5 million, a remarkable 92% growth driven by increased surgical procedures and new physician users.
- Improved Gross Margin: The company reported a gross profit of $1 million in Q4 2025, representing 69% of revenue, a substantial increase from 46% in Q4 2024, indicating progress in cost control and sales efficiency.
- Enhanced Financial Flexibility: Tenon Medical successfully completed a $2.85 million At-The-Market PIPE financing and a $4.3 million private placement of senior convertible notes, providing the financial flexibility necessary for expansion and product rollouts, laying a solid foundation for future growth.
- Net Loss Improvement: Although the company reported a net loss of $12.6 million for the full year 2025, this reflects an improvement from a $13.7 million loss in 2024, demonstrating the company's efforts and effectiveness in controlling losses.
See More
Tenon Medical (TNON) Q4 2025 Earnings Transcript
See More
Tenon Medical Reports Record Q4 2025 Revenue Growth and Strategic Developments
- Record Revenue Growth: Tenon Medical achieved a full-year revenue of $3.9 million in 2025, marking a 20% increase, with Q4 revenue reaching $1.5 million, a 92% rise year-over-year, indicating significant growth driven by increased surgical procedures across the Catamaran and SImmetry+ platforms.
- FDA 510(k) Clearance Milestone: The company received FDA 510(k) clearance for the next-generation SImmetry+ SI-Joint Fusion System, expanding its portfolio to include a complementary lateral approach alongside Catamaran, which is expected to drive future market demand and revenue growth.
- Financing and Investment Plans: Tenon completed a $2.85 million At-The-Market PIPE financing and a $4.3 million private placement of senior convertible notes, with proceeds aimed at funding commercial expansion, product launches, and clinical studies, ensuring the company’s ongoing growth and innovation capabilities.
- Gross Margin Improvement: The gross profit for Q4 was $1 million, representing 69% of revenue, a significant increase from 46% in the prior year, reflecting the company's success in cost control and operational efficiency, which is expected to lay the foundation for sustainable growth in 2026.
See More
